4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
4D Molecular Therapeutics Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into 4D Molecular Therapeutics, Inc. For Possible Securities Fraud And Investors Are Invited To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics Inc May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet
The mean of analysts' price targets for 4D Molecular Therapeutics (FDMT) points to a 225.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics (FDMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.77 per share a year ago.
